William J. Link, PhD
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
Tarsus Reports XDEMVY Revenue and Option‑Style Retina Deals. The article notes that Tarsus’s drug XDEMVY is now generating revenue to cover operating costs. It also explains that the company’s retina product deals are structured like options, potentially providing flexible upside. These developments may improve the company’s cash flow outlook and support future growth initiatives.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
Lucid Capital Markets Begins Coverage of LENSAR, Sets $11 Target. Lucid Capital Markets has started coverage on LENSAR and issued a positive rating. The firm set a price target of $11, which sits near the upper end of the company’s 52‑week range. The new outlook may attract attention from investors looking at LENSAR’s valuation relative to its peers. The coverage adds a fresh perspective to the market’s view of the stock.
Transaction History
| RXST | ▲ Buy | Grant | 37,037 | — | 6/17/2026 | View on chart |
| TARS | ▼ Sell | Open Market | 1,928 | $121K | 6/15/2026 | View on chart |
| TARS | ▼ Sell | Open Market | 10,572 | $655K | 6/15/2026 | View on chart |
| TARS | ▲ Buy | Option Exercise | 2,954 | — | 6/12/2026 | View on chart |
| LNSR | ▲ Buy | Grant | 17,421 | $0 | 6/3/2026 | View on chart |
| TARS | ▼ Sell | Open Market | 3,629 | $247K | 3/16/2026 | View on chart |
| TARS | ▼ Sell | Open Market | 8,378 | $578K | 3/16/2026 | View on chart |
| TARS | ▼ Sell | Open Market | 493 | $34K | 3/16/2026 | View on chart |
| TARS | ▼ Sell | Open Market | 5,046 | $408K | 12/15/2025 | View on chart |
| TARS | ▼ Sell | Open Market | 6,306 | $516K | 12/15/2025 | View on chart |
| TARS | ▼ Sell | Open Market | 1,148 | $95K | 12/15/2025 | View on chart |
| TARS | ▼ Sell | Open Market | 5,680 | $458K | 12/15/2025 | View on chart |
| TARS | ▼ Sell | Open Market | 4,766 | $388K | 12/15/2025 | View on chart |
| TARS | ▼ Sell | Gift | 2,000 | $0 | 9/16/2025 | View on chart |
| TARS | ▼ Sell | Open Market | 27,116 | $1.5M | 9/8/2025 | View on chart |
| TARS | ▲ Buy | Option Exercise | 3,350 | — | 6/13/2025 | View on chart |
| RXST | ▲ Buy | Grant | 10,752 | — | 6/3/2025 | View on chart |
| LNSR | ▲ Buy | Grant | 7,374 | $0 | 5/23/2025 | View on chart |
| TARS | ▼ Sell | Open Market | 5,021 | $133K | 8/12/2024 | View on chart |
| TARS | ▼ Sell | Open Market | 29,979 | $780K | 8/12/2024 | View on chart |
| TARS | ▼ Sell | Other | 27,116 | $0 | 8/12/2024 | View on chart |
| TARS | ▼ Sell | Other | 10,446 | $0 | 8/12/2024 | View on chart |
| TARS | ▼ Sell | Other | 74,892 | $0 | 8/12/2024 | View on chart |
| TARS | ▲ Buy | Option Exercise | 3,350 | — | 6/24/2024 | View on chart |
| RXST | ▲ Buy | Grant | 2,554 | — | 6/6/2024 | View on chart |
| LNSR | ▲ Buy | Grant | 22,000 | $0 | 5/7/2024 | View on chart |
| RXST | ▼ Sell | Open Market | 20,598 | $1.0M | 2/1/2024 | View on chart |
| RXST | ▼ Sell | Open Market | 7,652 | $383K | 2/1/2024 | View on chart |
| RXST | ▼ Sell | Gift | 3,000 | $0 | 2/1/2024 | View on chart |
| RXST | ▼ Sell | Other | 2,610 | $0 | 8/17/2023 | View on chart |
| RXST | ▼ Sell | Other | 21,248 | $0 | 8/17/2023 | View on chart |
| RXST | ▼ Sell | Other | 694,124 | $0 | 8/17/2023 | View on chart |
| TARS | ▲ Buy | Option Exercise | 2,000 | — | 6/16/2023 | View on chart |
| RXST | ▲ Buy | Grant | 5,731 | $0 | 6/1/2023 | View on chart |
| LNSR | ▲ Buy | Grant | 9,288 | $0 | 5/25/2023 | View on chart |
| TARS | ▼ Sell | Other | 215,576 | $0 | 5/11/2023 | View on chart |
| TARS | ▼ Sell | Other | 41,219 | $0 | 5/11/2023 | View on chart |
| RXST | ▼ Sell | Other | 258,390 | $0 | 5/11/2023 | View on chart |
| RXST | ▼ Sell | Other | 98,715 | $0 | 5/11/2023 | View on chart |
| TARS | ▼ Sell | Other | 215,575 | $0 | 3/15/2023 | View on chart |
| TARS | ▼ Sell | Other | 52,194 | $0 | 3/15/2023 | View on chart |
| TARS | ▼ Sell | Other | 215,575 | $0 | 11/10/2022 | View on chart |
| TARS | ▼ Sell | Other | 8,382 | $0 | 11/10/2022 | View on chart |
| RXST | ▼ Sell | Other | 316,694 | $0 | 11/9/2022 | View on chart |
| RXST | ▼ Sell | Other | 107,236 | $0 | 11/9/2022 | View on chart |
| TARS | ▼ Sell | Other | 3,749 | $0 | 8/15/2022 | View on chart |
| TARS | ▼ Sell | Other | 215,575 | $0 | 8/15/2022 | View on chart |
| RXST | ▼ Sell | Other | 107,236 | $0 | 8/10/2022 | View on chart |
| RXST | ▼ Sell | Other | 316,694 | $0 | 8/10/2022 | View on chart |
| RXST | ▼ Sell | Other | 126,979 | $0 | 6/8/2022 | View on chart |
| RXST | ▼ Sell | Other | 375,000 | $0 | 6/8/2022 | View on chart |
| RXST | ▲ Buy | Grant | 10,349 | $0 | 6/2/2022 | View on chart |
| LNSR | ▲ Buy | Grant | 4,285 | $0 | 5/25/2022 | View on chart |
| RXST | ▼ Sell | Other | 375,000 | $0 | 5/17/2022 | View on chart |
| RXST | ▼ Sell | Other | 375,000 | $0 | 3/15/2022 | View on chart |
| TARS | ▼ Sell | Other | 250,000 | $0 | 11/11/2021 | View on chart |
| TARS | ▼ Sell | Other | 4,348 | $0 | 11/11/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
BofA Lowers RxSight Target to $5.5 Amid Growth Headwinds
Bank of America analysts say RxSight's potential for utilization growth is limited by structural and competitive challenges. They lowered the price target to $5.50 and keep an underperform rating. The stock is trading near its 52‑week low and close to a support level of $4.88.
BofA Lowers RxSight Target to $5.5 Amid Growth Headwinds. Bank of America analysts say RxSight's potential for utilization growth is limited by structural and competitive challenges. They lowered the price target to $5.50 and keep an underperform rating. The stock is trading near its 52‑week low and close to a support level of $4.88.